Health Condition 1: H308- Other chorioretinal inflammations
Conditions
Interventions
Intervention1: Subtenon Triamcinolone injection and Intravitreal Methotrexate injection: Prospective pilot study comparing the effects of subtenon Triamcinolone and intravitreal Methotrexate in uveiti
Sponsors
All India Institute of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: a) Patient giving free and voluntary informed consent for enrolling into the study. b) Visual acuity less than 6/12. c) CMT more than 300 with evidence of cystoid edema idiopathic and serpiginous like choroiditis ( at least one active patch of choroiditis) d) Presence of either Vitritis or CME or Active vasculitis or Active choroiditis e) Acute as well as recurrent / chronic cases will be included. (Only patients with a recurrent episode who might have received a Posterior Subtenon Triamcinolone / Intravitreal Triamcinolone in the past 3 months will be excluded). Patients with a recurrent episode / chronic disease who might be on oral steroids and/ or oral Immunosuppressant can be included
Exclusion criteria
Exclusion criteria: a)Bilateral disease b)Fovea threatening Serpiginous Choroiditis c)Known steroid responders to be excluded from group 1 d)Infectious Uveitis e)Severe case of uveitis (vision very poor less than or equal to FCCF (log mar less than or equal to 2)), media clarity score of 5 (fundus not visible at all), CMT greater than 600 microns) in which the treating ophthalmologist might feel the need for a very rapid response would be excluded as these might require additional systemic steroids. f)Patients of idiopathic serpiginous like choroiditis if vision is good (vision > 6/18), and there is an active parafoveal patch of choroiditis. In these cases treatment protocol may be high dose oral steroids 1.5-2mg/Kg or pulse steroid. g)Patients who have received posterior Subtenon Triamcinolone in the past 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparing the subtenon Triamcinolone and intravitreal Methotrexate in uveitisTimepoint: Group-1 (PST)-Follow ups at 2 weeks ,1 month,3 month,6 month Group-2(Intravitreal MTX)-Folllow with in first 3 days of intravitreal,2 weeks,1 month,3 month,6 month PARAMETERS Vision,IOP,Anterior segment reaction,Media clarity,Fundus evaluation,OCT,FAF(as indicated),Specular microscopy (as indicated) | — |
Secondary
| Measure | Time frame |
|---|---|
| NilTimepoint: Nil | — |
Countries
India
Contacts
Public ContactDRRAHUL P VIJAYAKUMAR
All India Institute of Medical Sciences,New Delhi
Outcome results
None listed